Compare TWO & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | COLL |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | 486 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2015 |
| Metric | TWO | COLL |
|---|---|---|
| Price | $12.34 | $33.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $12.56 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 1.8M | 384.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $81.73 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $8.84 | $29.08 |
| 52 Week High | $14.17 | $50.79 |
| Indicator | TWO | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 47.84 |
| Support Level | $12.32 | $31.56 |
| Resistance Level | $12.70 | $35.95 |
| Average True Range (ATR) | 0.10 | 1.20 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 15.38 | 62.20 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, residential mortgage loans, mortgage servicing rights, and commercial real estate. The majority of its investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. The company derives revenues mainly from its MSR and Agency RMBS portfolio, including servicing fee income, float income, and interest income, as well as mortgage loan origination activities established to support the MSR portfolio. Its investment portfolio is subject to market risks, mainly interest rate, basis, and prepayment risk. The majority of income is generated by available-for-sale securities.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.